Fas-mediated apoptosis plays an important role in elimination of tumor cells in vivo, but some tumor-derived cells are resistant to this mechanism. Here, we show that treatment with the histone deacetylase (HDAC) inhibitor FR901228 renders Fas-resistant osteosarcoma cell lines sensitive to Fas-mediated apoptosis by downregulating expression of cellular FLIP (cellular FLICE-inhibitory protein), an inhibitor of Fas-mediated activation of caspase-8. Moreover, sensitization to Fas-mediated apoptosis was also induced in Fas-resistant osteosarcoma cells by suppressing FLIP expression using FLIP-specific RNA interference. HDAC inhibitors including FR901228 were shown to induce downregulation of cellular FLIP through inhibiting generation of FLIP mRNA, rather than stimulating degradation at either protein or mRNA level, and the inhibition was independent of de novo protein synthesis. These results clearly indicate that some tumor cells exhibit a phenotype resistant to death receptor-mediated apoptosis by expressing cellular FLIP, and that HDAC inhibitors sensitize such resistant tumor cells by directly downregulating cellular FLIP mRNA.
Introduction
Apoptosis is a form of cell death essential to embryonic development and maintenance of homeostasis.
1,2 While apoptotic dysfunction underlies various pathologies, including autoimmune and neurodegenerative diseases, apoptosis plays an especially important role in suppressing oncogenesis. Tumor-suppressor genes have been shown to induce apoptosis, which can be triggered by abnormal progression of the cell cycle caused by cellular or viral oncogenes, and defects in proapoptotic genes frequently result in tumorigenesis. 3 Histone acetylation, which is regulated by the balance of histone acetyltransferase and histone deacetylase (HDAC), plays an important role in regulation of gene expression by modulating chromatin structure. In general, acetylation and deacetylation of histones have been considered to be associated with transcriptional activation and repression, respectively. 4, 5 HDAC inhibitors, which have been reported to cause not only cell cycle arrest and differentiation but also apoptosis, can inhibit proliferation and survival of tumor cells. 6 Consequently, various HDAC inhibitors, including the natural cyclic depsipeptide FR901228, [7] [8] [9] [10] are under clinical development as novel drugs for cancer therapy. 6 Apoptosis has been shown to be induced through two main signaling pathways. These are referred to as the intrinsic and extrinsic pathways, and are mediated by the mitochondria 11 and by death receptors 12 such as Fas (Apo-1/CD95), 13 respectively. Apoptosis is executed by effector caspases, such as caspase-3 and caspase-7, which are in turn activated by cleavage by initiator caspases, such as caspase-8/FADDlike interleukin 1-converting enzyme (FLICE) and caspase-9. The proforms of caspase-8 and caspase-9 are initially activated by autocatalytic cleavage in death receptormediated and mitochondria-mediated apoptosis, respectively. Some classes of HDAC inhibitors have been reported to induce apoptosis by activating either caspase-8 or caspase-9 in various types of tumor cell lines. Molecular mechanisms of Fas-induced apoptosis have been intensively studied. Stimulation of Fas by Fas ligand (FasL) 12, 14 or agonistic anti-Fas antibody 13, 15 induces recruitment of the Fas-associated death domain (FADD) and procaspase-8, leading to activation of caspase-8 by autocatalytic cleavage of procaspase-8.
14,16 Activated caspase-8 cleaves and activates either effector caspases or the proapoptotic Bcl-2 family member protein, Bid. Cleaved Bid translocates to the mitochondria and induces activation of caspase-9, leading to the activation of effector caspases. 16 Importantly, Fas-mediated apoptosis has been reported to be inhibited by cellular FLICE-inhibitory protein (FLIP), through suppression of either recruitment of procaspase-8 by FADD or autocatalytic activation of caspase-8. 17 Cellular FLIP can be present in short and long forms (FLIP-S and FLIP-L, respectively), which are two splicing variants encoded by the same gene.
HDAC inhibitors have been reported to induce apoptosis through either the intrinsic or extrinsic apoptotic pathway. 6 In HDAC inhibitor-induced activation of death receptor-mediated apoptosis, upregulation of Fas and FasL occurs in cells derived from neuroblastoma, 18 promyelocytic leukemia, 19 and uveal melanoma. 20 In addition, downregulation of FLIP-L protein was reportedly induced by treatment of chronic lymphocytic leukemia cells with the HDAC inhibitors FR901228 and MS-275. 21, 22 Recently, we demonstrated that FR901228 not only induces upregulation of FasL but also shows synergistic apoptosis-inducing activity when costimulated with anti-Fas mAb in osteosarcoma cell lines. 23 Here, we show that the synergistic effect of FR901228 and anti-Fas mAb is mediated by FR901228-induced sensitization of Fasresistant osteosarcoma cell lines to Fas-induced apoptosis, and that this sensitization is directly induced by FR901228-induced downregulation of FLIP-S and FLIP-L at the mRNA level. These results show that some tumor cells develop resistance to Fas-mediated apoptosis by expressing FLIP, and that treatment with FR901228 renders such Fas-resistant tumor cells sensitive to Fas-induced apoptosis by downregulating the expression of FLIP.
Results

HDAC inhibitors sensitize tumor cell lines to Fasinduced apoptosis
We recently reported that the HDAC inhibitor FR901228 induces both activation of Fas-mediated signaling and expression of FasL in osteosarcoma cells, 23 and simultaneous stimulation with FR901228 and agonistic anti-Fas mAb shows synergistic induction of apoptosis in osteosarcoma cell lines. To clarify whether FR901228 induces sensitization of cells to Fas-induced apoptosis, we examined the effects of pretreatment with FR901228 on Fas-induced apoptosis. The osteosarcoma cell lines OST and U-2 OS were pretreated with FR901228 for 12 h, and then stimulated with agonistic antiFas mAb CH-11. While neither CH-11 alone nor FR901228 alone induced significant apoptosis in these cell lines, pretreatment with more than 2 nM of FR901228 highly sensitized the cells to agonistic anti-Fas mAb-induced apoptosis (Figure 1a and b) . In addition, simultaneous stimulation with FR901228 and CH-11 induced more rapid apoptosis in FR901228-pretreated cells than in cells that had not undergone pretreatment, and stimulation with CH-11 alone similarly induced apoptosis in FR901228-pretreated OST cells after washing out of FR901228 (data not shown). These results indicate that treatment with FR901228 renders Fas-resistant osteosarcoma-derived cells sensitive to Fasinduced apoptosis.
We also examined the effects of pretreatment with FR901228 on Fas-sensitive HeLa cells, in which the functions of p53 and Rb are inhibited. As shown in Figure 1a Representative data are shown from at least three independent experiments sodium butyrate, and the results indicated that these HDAC inhibitors also sensitize OST cells to Fas-induced apoptosis (data not shown).
To examine whether FR901228 stimulated Fas-induced activation/cleavage of caspases, Western blot analysis was performed for caspase-8, caspase-9, and caspase-3 in OST and U-2 OS cells ( Figure 2 ). While treatment of these cells with CH-11 alone or FR901228 alone induced very little cleavage of these proteins, Fas stimulation after pretreatment with FR901228 significantly induced cleavage of caspase-8, -9, and -3, and consequently the amounts of procaspase-8, -9, and -3 decreased after 8 h treatment with CH-11. These results indicate that FR901228 induces sensitization of tumor cell lines to Fas-mediated apoptosis by facilitating cleavage of caspases.
FR901228 downregulates expression of FLIP-S and FLIP-L at the protein level
To examine whether regulation of cell surface Fas expression is involved in FR901228-induced sensitization of cells to Fasmediated apoptosis, we analyzed the cell-surface expression level of Fas before and after treatment with FR901228 ( Figure 3a) . The results showed that cell-surface Fas expression was unchanged in OST, U-2 OS, and HeLa cells after treatment with FR901228 for 24 h. This indicates that FR901228 sensitizes cells to Fas-induced apoptosis by affecting the signaling pathway downstream of Fas. Hence, we analyzed the expression levels of molecules downstream from Fas in Fas-signaling pathways by Western blot analysis with antibodies specific for FADD, caspase-8, caspase-3, FLIP, Bid, Bax, Bcl-2, and Bcl-X L (Figure 3b ). FR901228 did not upregulate or downregulate the expression levels of FADD, caspase-8, caspase-3, Bid, Bax, Bcl-2, and Bcl-X L , while expression of FLIP-S and FLIP-L were highly downregulated after treatment of OST, U-2 OS, and HeLa cells with 
Downregulation of FLIP is sufficient for sensitization of cells to Fas-induced apoptosis
To evaluate the role of FR901228-induced downregulation of FLIP in Fas-mediated apoptosis in OST cells, we tried to suppress the expression of both FLIP-S and FLIP-L using the RNA interference (RNAi) method with a pSUPER vector system. Five kinds of RNAi constructs (pSUPER flip-1, -2, -3, -4, and -5; see Materials and Methods) were designed against FLIP mRNA, which corresponded to common sequences between cDNAs of FLIP-S and FLIP-L. Western blot analysis indicated that pSUPER flip-1, flip-4, or flip-5, and a mixture of them effectively decreased the levels of both FLIP-S and FLIP-L protein, while pSUPER flip-2 and -3 produced only a slight decrease in the FLIP-S and FLIP-L protein level (Figure 4a) .
We then analyzed the sensitivity of RNAi vector-transfected OST cells to Fas-mediated apoptosis. Cells were cotransfected with expression vectors for green fluorescence protein (GFP) and the RNAi constructs against FLIP, and Fasinduced activation of caspase-3 was quantified in GFPpositive cells (Figure 4b and c) . RNAi-induced downregulation We also carried out Terminal Deoxynucleotidyltransferasemediated dUTP Nick End Labeling (TUNEL) assay for detecting apoptotic cells in GFP-positive cells, which were enriched by a cell sorter after the cotransfection with expression vectors for GFP and the RNAi constructs against FLIP (Figure 4e and f) . RNAi-induced downregulation of FLIP-S and FLIP-L clearly sensitized OST cells to Fas-mediated apoptosis, and the sensitivity was indicated to be comparable to that of cells pretreated with FR901228. These results showed that downregulation of FLIP by either RNAi or HDAC inhibitors is sufficient to sensitize Fas-resistant osteosarcomaderived OST cells to Fas-induced apoptosis.
FR901228 induces downregulation of FLIP mRNA
It has recently been demonstrated that the level of cellular FLIP can be modulated not only by regulation of the transcription but also by degradation at the protein level through the ubiquitin-proteasome pathway. [24] [25] [26] To clarify whether FR901228-induced downregulation of FLIP is caused by degradation of FLIP protein or decreased FLIP mRNA expression, Northern blot analysis was carried out on OST, U-2 OS, and HeLa cells treated with FR901228, and compared to a similar analysis of untreated cells (Figure 5a) . The results showed that treatment with FR901228 notably decreases the expression level of mRNA for both FLIP-S and FLIP-L. This indicates that treatment with FR901228 sensitized the tumor cell lines to Fas-mediated apoptosis by downregulating FLIP mRNA.
Since it is well known that HDAC inhibitors activate the transcription of a certain set of genes, 5 we examined whether FR901228-induced downregulation of FLIP mRNA expression was mediated by de novo protein synthesis. OST cells were pretreated with 10 mg/ml cycloheximide for 1 h, followed by cultivation with FR901228 in the presence of cycloheximide for 12 h. As shown in Figure 5a , treatment with cycloheximide did not inhibit the FR901228-induced downregulation of FLIP mRNA expression, indicating that this process is not dependent on de novo protein synthesis. To confirm that the concentration of cycloheximide (10 mg/ml) was sufficient to suppress protein synthesis, we quantified [
35 S]methionine The results showed that 10 mg/ ml cycloheximide or 10 mg/ml cycloheximide plus 10 nM FR901228 decreased protein synthesis by 6.5 and 6.6%, respectively, compared to that in the absence of cycloheximide.
We then examined whether the FR901228-induced downregulation of FLIP was caused by reduction of RNA synthesis or stimulation of RNA degradation. Northern blot analysis was performed in OST cells pretreated with 1 mg/ml actinomycin D for 1 h and cultured with or without FR901228 in the presence of actinomycin D for 4 or 12 h. As shown in Figure 5b 
Discussion
Although the synergistic induction of apoptosis has been previously reported for the simultaneous stimulation of death receptors with HDAC inhibitors, 23, [27] [28] [29] the data in this manuscript indicate that pretreatment with the HDAC inhibitor FR901228 causes sensitization to Fas-mediated apoptosis through suppression of FLIP mRNA expression. In addition, downregulation of FLIP by RNAi was shown to be sufficient to sensitize death receptor-resistant OST cells to Fas-and TRAIL-induced apoptosis. All the data clearly indicate that the HDAC inhibitor FR901228 renders Fas-resistant tumor cells sensitive to Fas-induced apoptosis by downregulating FLIP mRNA through inhibition of its transcription.
We also analyzed the effect of two other classes of HDAC inhibitors, Trichostatin A and butyrate, and showed that they can similarly decrease the FLIP mRNA level (Figure 5b ) and sensitize OST cells to Fas-induced apoptosis (data not shown). Therefore, the effect of FR901228 may be based on its HDAC inhibitory activity. While HDAC inhibitors are generally regarded as transcriptional activators, we demonstrated that FR901228 downregulates FLIP mRNA through suppression of its generation that is independent of de novo protein synthesis (Figure 5a and b) . In addition, FR901228 did not enhance the degradation of FLIP protein (Figure 5c ). Thus, FR901228 might directly induce inhibition of FLIP gene transcription. Interestingly, HDAC inhibitors have been suggested to induce both activation and suppression of transcription, since treatment with such inhibitors causes the upregulation and downregulation of an approximately equal numbers of genes. 30 Therefore, our result showing that FR901228 induces transcriptional downregulation of FLIP without de novo protein synthesis is plausible, but its mechanism remains an open question.
Previous reports have shown HDAC inhibitor-induced upregulation of Fas, [18] [19] [20] FasL, 23 and Bax 31 and downregulation of Bcl-X L . 29, 32 On the contrary, we did not observe changes in Fas and Bcl-X L expression following treatment of OST, U-2 OS, and HeLa cells with FR901228 (Figure 3b) . The difference between previous reports and our results may be due to cell type-specific effects. However, we believe that downregulation of FLIP by HDAC inhibitors may be a more general effect than the regulation of Fas, FasL, Bax, and Bcl-X L , since we observed FR901228-induced downregulation of FLIP in embryonic fibroblasts and T-lymphoma cell lines, as well as in OST, U-2 OS, and HeLa cells (Figure 3b and data not shown). We note that previously reported gene expression profile experiments have not shown HDAC inhibitor-induced downregulation of FLIP mRNA, 30, 33, 34 suggesting that the basal level of FLIP mRNA was not high enough for detection under the experimental conditions used in these studies. 6 Death receptor-induced apoptosis by recombinant TRAIL 35 or agonistic anti-Fas mAb without indication of hepatotoxicity 36 has also been explored as a cancer therapy. Many tumor cells are, however, resistant to Fas-mediated apoptosis, despite the cell-surface expression of Fas. 37 Here, we have demonstrated that FR901228 renders Fas-resistant OST and U-2 OS cells sensitive to Fas-induced apoptosis by downregulating FLIP. The expression levels of FLIP-S and FLIP-L in these cells were not especially high compared to other tumor cells (data not shown), and downregulation of FLIP by RNAi was clearly shown to be sufficient to confer sensitivity to death receptormediated apoptosis in OST cells (Figure 4) . These results suggest that the synergistic effect of combination treatment with an HDAC inhibitor and a death-receptor-stimulant, or with FLIP antagonists including FLIP RNAi and a death-receptorstimulant may not be specific to the restricted number of cell lines examined here, but may be general over a broad range of tumor cells. In fact, HeLa cells, in which both p53 and Rb are functionally defective, as observed in many tumor cells, showed much higher sensitivity to Fas-induced apoptosis following treatment with FR901228 (Figure 1) , with associated downregulation of FLIP (Figure 3b and 5) . Our proposed molecular mechanism of synergistic induction of apoptosis by death receptor stimulation and HDAC inhibitor treatment may open the door to combination cancer therapy using this approach.
Materials and Methods
Cell lines
Human osteosarcoma cell lines, OST and U-2 OS, and human adenocarcinoma-derived HeLa cells were provided by Dr Souichi Adachi (Graduate School of Medicine, Kyoto University) and Dr Yoshihide Tsujimoto (Osaka University Medical School), respectively. Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Nacalai Tesque) containing 10% heat-inactivated fetal bovine serum, 100 U penicillin, and 100 mg/ml streptomycin at 371C in 5% CO 2 .
Reagents and antibodies
FR901228 was a gift from Fujisawa Pharmaceutical Co. Ltd., Japan. Agonistic anti-Fas mAb CH-11 and antagonistic anti-Fas mAb ZB4 were obtained from Medical and Biological Laboratories (MBL), Japan. Anti-FLIP mAb Dave-2, mouse anti-actin mAb MAB1501R, and goat anti-rat IgG antibody were purchased from Alexis Biochemicals, Chemicon International and Santa Cruz Biotechnology, respectively. Anti-caspase-8 mAb 1C12, anti-caspase-9 antibody, anti-caspase-3 antibody, anti-Bid antibody, anti-Bax antibody, and anti-mouse IgG antibody were purchased from Cell Signaling Technology. Anti-Bcl-2 antibody and anti-Bcl-X L mAb were purchased from BD Biosciences. Z-VAD-fmk was purchased from Peptide institute, Inc., Japan. Cycloheximide and actinomycin D were purchased from Nacalai Tesque, Inc., Japan.
DNA content analysis for detection of apoptosis
Cells in which apoptosis had been induced were harvested, washed with PBS and fixed in 70% ethanol for at least 2 h at À301C. After washing with PBS, cells were treated with PBS containing 0.25 mg/ml RNase at 371C for 15 min and then incubated with 50 mg/ml propidium iodide (PI) at 41C for 30 min in the dark. Cells were analyzed with an EPICS XLt Flow Cytometer (Beckman Coulter). Subdiploid (sub-G1) populations were calculated as an estimate of the apoptotic cell population.
Western blot analysis
Cells were lysed in cold lysis buffer (50 mM Tris-HCl, pH 8.0 with 10% glycerol, 1% Nonidet P-40, 50 mM NaCl, 2 mM EDTA, and 1 mM DTT) containing 1% (v/v) of protease inhibitor cocktail (Sigma) and 1 mM PMSF. Cell lysate was centrifuged at 15 000 r.p.m. for 20 min and the resulting supernatant was resolved by SDS-PAGE and transferred to an Immobilon transfer membrane (Millipore). The immunoblotting assay was performed Figure 5 FR901228-induced downregulation of FLIP mRNA and its effect on FLIP protein expression. (a) After pretreatment with or without 10 mg/ml cycloheximide (CHX) for 1 h, OST, U-2 OS, and HeLa cells were cultured with or without 10 nM FR901228 (FR) for 12 h in the presence or absence of CHX. RNA was extracted, and Northern blot analyses for FLIP and EF1a mRNA were carried out. FLIP level indicates the ratio of quantified amounts of FLIP-S mRNA to those of control cells not treated with FR or CHX, which were normalized with those of EF1a mRNA. (b) After pretreatment with or without 1 mg/ml actinomycin D for 1 h, OST cells were cultured with or without 10 nM FR901228, 10 nM Trichostatin A (TSA), or 20 mM sodium butyrate (butyrate) for 12 h in the presence or absence of actinomycin D, and then Northern blot analysis was performed as described in (a). (c) After pretreatment with or without 10 mg/ml CHX for 1 h, OST cells were cultured with or without 10 nM FR901228 for the indicated time in the presence of CHX. Then, the expression levels of FLIP-S and actin were analyzed by Western blotting using a specific primary antibody and a peroxidase-conjugated secondary antibody, as described previously. 38 
RNA interference analysis for FLIP
The pSUPER RNAi system (OligoEngine) was used in RNA interference suppression of FLIP expression. Five kinds of pSUPER vectors were designed, and these are referred to as pSUPER flip-1, -2, -3, -4, and -5. These included 19-nucleotide sequences of FLIP cDNA starting at nucleotide (nt) 139, nt 140, nt 172, nt 230, and nt 258, respectively, and all sequences were common to both FLIP-S and FLIP-L cDNA. pSUPER flipmix refers to a mixture of flip-1, -4, and -5.
Analysis of caspase-3 activation in various transfectants
Cells in six-well plates were transfected with 0.2 mg expression vector for EGFP 39 together with 0.8 mg pSUPER vector for RNAi against FLIP or with pCMV-Tag2B (Stratagene) encoding FLIP-S (0.025 mg) and FLIP-L (0.025 mg) using Lipofectamine Plus (Invitrogen), in accordance with the manufacturer's instructions. The total amount of DNA for each transfection was adjusted to 1.0 mg per sample by adding empty vector. After incubation for 24 h, cells were pretreated for 12 h with 10 nM FR901228 in the culture medium and then stimulated with 250 ng/ml anti-Fas mAb CH-11 or 250 ng/ml TRAIL. Cells were permeabilized, fixed, and then stained with phycoerythrin (PE)-conjugated anti-active caspase-3 mAb (BD Bioscience), in accordance with the manufacturer's instructions. GFPpositive cells (vector-transfected cells) and PE-positive cells (caspase-3-active cells) were simultaneously analyzed by flow cytometry.
TUNEL assay
Cells in 100 mm dishes were transfected with GFP expression vector together with pSUPER vectors for RNAi against FLIP. After 20 h of cultivation, GFP-positive cells were highly enriched by a cell sorter, MoFlo flow Cytometer (Cytomation). Subsequently, cells were washed twice with culture medium and plated. After 5 h cultivation, adherent cells were treated for 12 h with 10 nM FR901228, and then stimulated with 250 ng/ml anti-Fas mAb CH-11 for 15 h. DNA nick ends in cells were labeled with biotinylated dUTP by terminal deoxynucleotidyl transferase and then stained with streptavidin-PE using MEBSTATIN Apoptosis Kit 2 (MBL, Japan).
Northern blot analysis
RNA was isolated from cells using Isogen (Nippongene, Tokyo, Japan) and Northern hybridization was performed, as described previously, 40 using full-length human FLIP cDNA, which recognizes nt 1-666 of FLIP-S and nt 1-609 of FLIP-L, and full-length human EF1a cDNA as probes for detection of FLIP and EF1a mRNA, respectively.
